← Human Trials & Peer-Reviewed Studies
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
Plain-language guide to PMID 33039693 (2020): randomized and double-blind clinical study of Semaglutide in 320 patients.
Key Facts
- PMID
- 33039693
- Journal
- Contemporary clinical trials
- Year
- 2020
- Study type
- Clinical Study
- Authors
- Harrison SA et al. (9 authors)
- DOI
- 10.1016/j.cct.2020.106174
What This Study Did, in Plain Language
What Was Tested
This clinical study looks at Semaglutide.
Exploratory analyses were performed to evaluate correlations between baseline parameters and biomarkers in NASH.
Why It Was Studied
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease.
The researchers describe a trial of semaglutide treatment for NASH, identify key patient characteristics and compare the relationship of patient characteristics and non-invasive biomarkers/scores.
Who Took Part
According to the abstract, 320 patients were involved.
PubMed indexes the participants as middle-aged adults.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.
What Was Measured
The researchers describe a trial of semaglutide treatment for NASH, identify key patient characteristics and compare the relationship of patient characteristics and non-invasive biomarkers/scores.
PubMed files the paper under topics including Biomarkers, Biopsy, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease and Randomized Controlled Trials as Topic.
The authors tagged it with the keywords Clinical trial protocol, General diabetes, Hepatology and Semaglutide.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 320 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2020 (Contemporary clinical trials), a journal based in United States.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.